Standard BioTools Inc
NASDAQ:LAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Acreage Holdings Inc
OTC:ACRDF
|
US |
Standard BioTools Inc
Free Cash Flow
Standard BioTools Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Standard BioTools Inc
NASDAQ:LAB
|
Free Cash Flow
-$82.6m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-6%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Free Cash Flow
$6.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Free Cash Flow
$5.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
5%
|
|
|
Waters Corp
NYSE:WAT
|
Free Cash Flow
$539.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Free Cash Flow
$993m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Free Cash Flow
$2.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
Standard BioTools Inc
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
See Also
What is Standard BioTools Inc's Free Cash Flow?
Free Cash Flow
-82.6m
USD
Based on the financial report for Dec 31, 2025, Standard BioTools Inc's Free Cash Flow amounts to -82.6m USD.
What is Standard BioTools Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-6%
Over the last year, the Free Cash Flow growth was 46%. The average annual Free Cash Flow growth rates for Standard BioTools Inc have been 4% over the past three years , -24% over the past five years , and -6% over the past ten years .
